Abstract
Approved first-line (1L) treatments for BRAF-mutant (BRAF-MT) advanced melanoma include nivolumab plus ipilimumab (NIVO + IPI), anti–PD-1 monotherapy, and BRAF plus MEK inhibitors (BRAFi + MEKi). Clinical trial data comparing these options are limited. A real-world study in patients (pts) with BRAF-MT melanoma showed 3-year overall survival (OS) of 58% and 27% with NIVO + IPI and BRAFi + MEKi, respectively (Pavlick AC, et al. EADO 2020). The longer-term follow-up is presented here.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
